Aurobindo Pharma’s wholly owned subsidiary-- Eugia Pharma Specialities has started distribution of aseptic products manufactured at Unit III, that was temporarily stopped. The company also expects to start commercial production from the aseptic lines of the said facility in a phased manner beginning next week and to re-start all the lines by April 15, 2024.
Earlier, Eugia Pharma Specialities had restarted production in its terminally sterilized product lines at its Unit-III. The production was temporarily stopped to address some of the observations of United States Food and Drug Administration (USFDA) in their recent inspection concluded on February 2, 2024.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1777.65 |
Dr. Reddys Lab | 1194.55 |
Cipla | 1465.65 |
Lupin | 2043.30 |
Zydus Lifesciences | 944.25 |
View more.. |